Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 25fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 15Etoposide 13Cyclosporine 13Mycophenolic Acid 12Busulfan 12Tacrolimus 11Filgrastim 11Antilymphocyte Serum 11Methotrexate 9Prednisone 8Dexamethasone 8nelarabine 7Radiotherapy 7Doxorubicin 7Vincristine 6Methylprednisolone 6Calcium Dobesilate 6Vorinostat 5Paclitaxel 5Lenalidomide 5Everolimus 5Carboplatin 5Bortezomib 5merphos 4aldesleukin 4Therapeutics 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × BMS-906024 × Clear all
NCT01363817 2019-07-30

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
31 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡